Bonadio RC, Amor Divino PH, Obando JSM, et al. - In a single-center retrospective analysis of 54 individuals with borderline or unresectable (B/U) liver metastases from colorectal cancer (CRC) treated with conversion chemotherapy with the modified fluorouracil, leucovorin, and oxaliplatin (mFLOX) regimen followed by metastasectomy, experts assessed the surgical and survival outcomes of such individuals. Cure of B/U liver metastases from CRC with conversion chemotherapy using a mFLOX regimen followed by surgical resection was discovered to be related to a high R0 resection rate and favorable survival outcomes. Based on the results, amongst other options that have been suggested, mFLOX was acknowledged as a low-cost alternative for conversion chemotherapy.